Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

B7-33

£8.39£30.86

Buy B7-33 Peptide Vial 

B7-33 has powerful anti-fibrotic properties. Chronic and acute diseases like heart failure, inflammation of the lungs or the kidneys can all be helped by reducing fibrosis. B7-33 has been shown in animal studies to minimise fibrosis resulting in prolonged survival following injury and providing the treatment for heart failure.

Buy 10 and get 10% Discount

417 in stock

Description

B7-33 Peptide Vial  New Zealand

This product is intended for research purposes only. To be used by trained professionals only.

B7-33 is a synthetic peptide derived from human relaxin-2, which is a hormone that plays a role in the regulation of several physiological processes, including vascular function, inflammation, and tissue repair. B7-33 has been shown to replicate the vasoprotective functions of human relaxin-2, and has been found to have therapeutic potential in several disease states.

New Zealand Research has shown that B7 33 can promote tissue repair and reduce fibrotic encapsulation. One study found that coatings containing B7-33 were able to reduce fibrotic encapsulation in implantable devices, suggesting that the peptide may have potential in improving the biocompatibility of such devices [1]. Additionally, B7 33 has been shown to prevent the development of endothelial dysfunction, indicating its potential in the treatment of cardiovascular diseases.

Furthermore, B7-33  peptide has been shown to attenuate adverse cardiac remodelling after myocardial infarction (MI) in mice. A study found that long-term administration of B7 33 led to improved cardiac function and decreased fibrosis in mice with MI, suggesting that the peptide may have therapeutic potential in the treatment of heart disease [2].

Studies have also explored the potential of B7 33 in inhibiting pancreatic cancer liver metastasis. A lipidated derivative of B7-33 was found to prolong the half-life of the peptide in vivo and improve its efficacy in inhibiting cancer cell migration and invasion. This suggests that B7-33 may have potential therapeutic uses in cancer treatment [3].

Overall, B7-33 has shown promising results in promoting tissue repair, reducing fibrosis and inflammation, and improving cardiovascular health. However, further New Zealand research is needed to fully understand the mechanisms of action and potential applications of this peptide.


References:

[1] https://pubmed.ncbi.nlm.nih.gov/ 31713411/

[2] https://www.ahajournals.org/ doi/10.1161/JAHA.119.0157 48

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7674520/


Sequence: VIKLSGRELVRAQIAISGMSTWS KRSL

Storage: Lyophilized peptides stored below -18°C.

Research use only. Not for human or animal consumption!

B7-33 HPLC 2023 Certificates_DIRECT PEPTIDES

 

 

 

 

 

 

 

 


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our New Zealand Direct Peptides website: https://new-zealand.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.


Buy B7-33 Peptide Vial Online today from New Zealand Direct Peptides 

You may also like…